Public Health
Latest news
417 articles · 20 / page
Daily High‑Dose Mosnodenvir Significantly Lowers DENV‑3 Viremia in a Human Challenge — Proof‑of‑Concept with Early Resistance Signals
In a phase 2a human challenge, high‑dose daily mosnodenvir substantially reduced DENV‑3 RNA burden versus placebo without serious adverse events, but treatment‑associated NS4B viral mutations emerged, highlighting efficacy and resistance co
Combining Food Biodiversity, Less Processing, and the EAT‑Lancet Diet Improves Nutrient Adequacy and Lowers Environmental Impact: Insights from 368,733 EPIC Participants
Multi-objective optimization in the EPIC cohort shows that modest gains in adherence to the EAT‑Lancet diet, increased plant species richness, and substitution of ultra‑processed foods with minimally processed foods can raise nutrient adequ
More Than Half of Hispanic Medicare Beneficiaries Aged 65+ Have Hearing Loss — Yet Few Use Hearing Aids
A nationally representative 2022 study found hearing loss in 54.6% of Hispanic US adults 65+; only 8.3% of those with hearing loss reported using hearing aids, underscoring major access gaps.
Invisible Invaders: How Microplastics May Accelerate Atherosclerosis — and Why Men Could Be at Greater Risk
New animal research links oral microplastic exposure to dramatic increases in arterial plaque—especially in males—by injuring endothelial cells and provoking inflammation and oxidative stress.
Geographic Clusters of Late-Life Epilepsy in US Medicare: Sleep and Mobility as Key Contextual Drivers
A Medicare cohort study mapped incident epilepsy among older adults across the contiguous US and linked high-incidence areas to social and environmental determinants—most strongly insufficient sleep and lack of household vehicle access—sugg
Rising Inhaler Emissions in the US: 1.6 Billion Devices, 25 Million Tons CO2e, and $5.7B in Social Costs
A JAMA serial cross‑sectional analysis finds US outpatient inhaler dispensing (2014–2024) produced ~24.9 million metric tons CO2e, mostly from metered‑dose inhalers; policy and clinical shifts to dry‑powder/soft‑mist devices and low‑GWP pro
High, Persistent Breast Cancer Mortality in Sub‑Saharan Africa: 7‑Year ABC‑DO Cohort Reveals Major Survival Gaps and Actionable Targets
A 7‑year follow-up of 2,153 women in the ABC‑DO cohort shows poor breast cancer survival in much of sub‑Saharan Africa, with 5‑year crude survival 40% and marked between-country and racial disparities; reaching WHO stage downstaging targets
Most Adolescents and Young Adults with Solid Tumours Reach Near-Normal 5-Year Survival Within Four Years — Implications for ‘Right to be Forgotten’ Policies
Population-based Dutch data show that AYA survivors of most solid malignancies achieve five-year conditional relative survival >95% by four years post-diagnosis, supporting reconsideration of blanket 10‑year disclosure periods in Right to B
Immunogenicity and HPV Infection After One, Two, and Three Doses of Quadrivalent HPV Vaccine in Indian Girls: A Multicentre Prospective Cohort Study
This study evaluates immune responses and HPV infection rates in Indian girls after receiving one, two, or three doses of the quadrivalent HPV vaccine, supporting WHO’s recommendation for two doses spaced at least six months apart.
Single-dose Cervarix induces durable seropositivity but fails HPV‑16 GMC non-inferiority versus three-dose Gardasil-4: implications from the PRIMAVERA immunobridging trial
PRIMAVERA immunobridging shows single-dose Cervarix induces near-universal seropositivity at 36 months and non-inferior HPV-18 antibodies versus three-dose Gardasil-4, but HPV-16 antibody GMCs were lower; results inform but do not yet suppo
Rare but Real: Higher Risks of Vascular and Inflammatory Disease After SARS‑CoV‑2 Infection Than After BNT162b2 Vaccination in Children and Adolescents
A nationwide English cohort study (n≈13.9M) found transient but significant increases in rare vascular and inflammatory events after first SARS‑CoV‑2 infection and a smaller, short-lived increase in myocarditis/pericarditis after first BNT1
Human Monoclonal Antibody MAM01 for Malaria Prevention: Phase 1 Trial Insights and Context in Antimalarial Monoclonal Antibody Development
This review synthesizes evidence on MAM01, a monoclonal antibody targeting Plasmodium falciparum circumsporozoite protein, summarizing its first-in-human phase 1 trial demonstrating safety and protective efficacy, alongside contextual advan
A Standard Set for Healthy Aging in Primary Care: Key Recommendations from the New Core Outcome Set (COS) Consensus
A concise overview of the newly developed Core Outcome Set for healthy aging in primary care—12 prioritized outcomes to standardize evaluation of health-promotion interventions and improve comparability across studies and programs.
What, When and How to Measure Post COVID-19 Condition: The New Core Outcome Set for Clinical Trials
A concise guide to the newly published Core Outcome Set for Post COVID-19 Condition (COS‑PCC): the nine prioritized outcomes, recommended measurement instruments, timing considerations, and implications for research and care.
DEN-CORE: An international consensus COMS to standardise dengue clinical trials
An international Delphi consensus defined a Core Outcome Measurement Set (COMS) for dengue trials to harmonise outcome selection and measurement across settings, improving comparability and evidence synthesis.
Marburg Virus Disease in Rwanda, 2024: Epidemiology, Clinical Management, and Public Health Response
This review synthesizes evidence from Rwanda’s 2024 Marburg virus disease outbreak, highlighting epidemiologic characteristics, clinical presentations, investigational therapeutics, and vaccine deployment strategies that contributed to outb
Long-Term Clinical and Immunological Landscape Following Monkeypox Virus Infection and MVA-BN Vaccination: Insights from the Belgian MPX-COHORT and POQS-FU-PLUS Studies
This review synthesizes 24-month follow-up data on monkeypox virus infection and MVA-BN vaccination, detailing durable immunity post-infection, comparative antibody kinetics, and clinical sequelae, informing future vaccination strategies an
A Single Shot Against Rift Valley Fever? Phase 1 ChAdOx1 RVF Trial Shows Acceptable Safety and Robust Immune Responses in Uganda
In a randomized, placebo-controlled phase 1 trial in Uganda, a single intramuscular dose of ChAdOx1 RVF (adenovirus-vectored) was well tolerated and induced rapid T-cell responses and neutralising antibodies, supporting further evaluation o
Targeted Vaccination Is Most Efficient but Not Cost‑Effective: National Serosurvey and Modelling of Japanese Encephalitis in Bangladesh
A nationally representative serosurvey and transmission modelling study in Bangladesh estimates low population-level JEV exposure but large numbers of infections annually; spatially targeted vaccination would be most efficient, though not c
Post‑COVID Resurgence of Mycoplasma pneumoniae in French Children: Hospital Burden, Risk Factors for ICU Admission, and Clinical Implications
A nationwide French multicentre cohort (ORIGAMI) documents a substantial 2023–24 paediatric hospitalisation surge from Mycoplasma pneumoniae, identifies older age, asthma, comorbidity and erythema multiforme as ICU risk factors, and highlig
Browse by specialty
Open language-specific specialty feeds and department pages.